Share

Profile & Fundamentals

Doximity Profile & Fundamentals

Name: Doximity financial chart data preview
Creator: iPulse AI
License: https://ipulseai.com/terms

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables

Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Jump directly to any section

Company and Market Context

Company Profile & Ownership

Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools, including Ask, a HIPAA-compliant AI assistant, to access and apply evidence-based medical information within clinical workflows; Scribe, a HIPAA-compliant, AI-powered clinical documentation tool; Telehealth tools for hospitals and health systems; and AMiON, an on-call scheduling tool. The company primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.

Company profile record

Doximity Inc

Common Stock · Health Care · Health Care Technology

Official website

Company

Company / asset: Doximity Inc
Security type: Common Stock
Sector: Health Care
Industry: Health Care Technology
HQ: 🇺🇸 United States
Head office: 500 3rd Street, San Francisco, CA, United States, 94107

Leadership & scale

Chief executive: Mr. Jeffrey A. Tangney
CEO year born: 1973
Full-time employees: 880
Fiscal year end: March
IPO date: 2021-06-24

Fundamentals snapshot

Updated 2026-09-13

Market Cap: USD 5.0B
P/E: 29.9x
Revenue (Q2 26): USD 156.6M
Profit (Q2 26): USD 24.3M
Dividend Yield: --
Revenue (FY 26): USD 644.9M
Shares in public float: 123.6M
Insider ownership: 2.86%

Reporting & identifiers

Symbol: DOCS.NYSE
Listing: 🇺🇸 United States | Dividend Tax: 30%
Ticker Currency: USD
Income Statement Currency: USD
Balance Sheet Currency: USD
Cash Flow Currency: USD
EPS Currency: USD
Contract Type: SPOT
ISIN: US26622P1075
Asset ID: equity_c864ecb9-9c8f-51c3-908b-f06268302528

Ownership

Shares Outstanding

Shares outstanding

Annual reported shares outstanding. Values in shares.

Top holders

BlackRock Inc14,256,525 shares · 8.00% · Reported 2026-03-31
Vanguard Portfolio Management, LLC6,394,107 shares · 3.59% · Reported 2026-03-31
D. E. Shaw & Co LP5,922,188 shares · 3.32% · Reported 2026-06-30
Vanguard Capital Management, LLC5,765,063 shares · 3.23% · Reported 2026-03-31
ClearBridge Advisors, LLC4,975,398 shares · 2.79% · Reported 2026-03-31
iShares Core S&P Mid-Cap ETF4,685,484 shares · 2.63% · Reported 2026-08-31
Two Sigma Investments LLC4,647,309 shares · 2.61% · Reported 2026-06-30

View more holders (8)

Carmignac Gestion4,311,997 shares · 2.42% · Reported 2026-03-31
Vanguard MStar Total Stk Mkt Idx Invest4,218,967 shares · 2.37% · Reported 2026-07-31
State Street Corp4,039,510 shares · 2.27% · Reported 2026-03-31
Geode Capital Management, LLC3,944,586 shares · 2.21% · Reported 2026-03-31
Wellington Management Company LLP3,135,113 shares · 1.76% · Reported 2026-06-30
Renaissance Technologies Corp3,059,749 shares · 1.72% · Reported 2026-03-31
Vanguard Small Cap Index3,032,747 shares · 1.70% · Reported 2026-07-31
Deutsche Bank AG2,922,774 shares · 1.64% · Reported 2026-03-31

Earnings, Profitability & Valuation

Earnings & Revenue

AI Review

The company is currently experiencing a tale of two financial statements. On one hand, sales growth has slowed down significantly from its pandemic-era highs, and net income has dropped due to a big jump in spending on artificial intelligence technology. On the other hand, the company's cash generation remains absolutely spectacular, bringing in a record amount of free cash flow that represents nearly half of its total revenue. The reports strongly agree that this cash-flow engine is incredibly healthy and provides a solid safety net. However, there is a clear disagreement on the future outlook: some believe that sales will quickly bounce back as drug companies return to the platform, while others worry that the slowdown is permanent and that high technology costs will continue to eat into profits. Overall, the massive cash flow is being used to buy back shares, which helps protect investors.

Revenue, Net Income, and Free Cash Flow

Revenue
Free cash flow
Net income

Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

Published P/E

Published valuation snapshots. Trailing four-quarter earnings where available; annual earnings otherwise. Non-positive earnings are omitted. Values in times earnings.

Profitability & Margins

AI Review

The company's core profitability remains exceptionally strong, highlighted by gross margins near ninety percent, meaning it costs almost nothing to serve each additional user on the platform. However, operating margins have recently shrunk because the company is spending heavily on artificial intelligence and computer power. The reports agree that this margin squeeze is happening, but they clash on what comes next. Some believe this is a temporary dip and that profit margins will bounce back once the new AI tools are fully built and start making money. Others argue that running advanced AI tools is structurally more expensive than running a simple social network, meaning may never return to their historical highs. Despite this squeeze, the company remains far more profitable than the average business, making its current valuation look highly attractive to cash-focused investors.

Profitability Margins

Gross margin
Operating margin
Net margin
Free cash flow margin

Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Sign in to check access View Base plan

Paywalled preview begins: Reported Data Tables — chart preview

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Reported Data Tables — chart preview

The following tables contain the same values as the financial charts above. Monetary values are USD; margins are percentages. Missing inputs are not estimated. Use is subject to the iPulse AI Terms of Service and applicable source rights.

Source: eodhd. Statement snapshots with chart transformations and ratios calculated by iPulse AI. Snapshot retrieved 2026-09-15.

Annual earnings and profitability
Period end	Revenue	Free cash flow	Net income	Gross margin	Operating margin	Net margin	Free cash flow margin
2019-03-31	85,695,000	14,116,000	7,833,000	87.29	8.08	9.14	16.47
2020-03-31	116,388,000	21,955,000	29,737,000	87.2	19.04	25.55	18.86
2021-03-31	206,897,000	78,363,000	50,210,000	84.92	25.76	24.27	37.88
2022-03-31	343,548,000	120,878,000	154,783,000	88.42	33.05	45.05	35.19
2023-03-31	419,052,000	173,418,000	112,818,000	87.24	29.86	26.92	41.38
2024-03-31	475,422,000	178,295,000	147,582,000	89.34	34.47	31.04	37.5
2025-03-31	570,399,000	266,740,000	223,185,000	90.2	39.94	39.13	46.76
2026-03-31	644,863,000	317,495,000	196,051,000	89.09	33.33	30.4	49.23

Published valuation snapshots
Period end	P/E (times earnings)	Earnings basis
2026-03-31	23.18	Trailing four quarters
2025-03-31	51.8	Trailing four quarters
2024-03-31	36.88	Trailing four quarters
2023-03-31	57.54	Annual net income
2022-03-31	71.37	Annual net income

Shares outstanding — chart values
Reporting date	Shares outstanding
2019-01-01	181,702,500
2020-01-01	185,207,000
2021-01-01	216,396,000
2022-01-01	212,065,000
2023-01-01	200,463,000
2024-01-01	202,233,000
2025-01-01	199,224,000
2026-01-01	191,169,000

End of the paywalled preview

The excerpt from Reported Data Tables — chart preview to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Earnings, Profitability & Valuation
- Complete profitability ratios
- EPS history and estimate comparisons
- Execution vs expectations
- Annual and quarterly financial views
Capital Expenditure & R&D
- Capital allocation AI review
- Annual capital expenditure
- Investment intensity trends
- Capex and R&D intensity indicators
Balance Sheet
- Balance sheet AI review
- Assets, debt and equity
- Capital structure
- Liquidity and leverage
- Retained earnings
Dividends & Actions
- Cash dividends paid
- Dividend indicators
- Buybacks and issuance
- Combined shareholder returns
- Available corporate actions
Company Events
- Dated insider transactions
- Material company activity

Explore complete public research examples

These public assets show the complete asset profiles, fundamental datasets and analysis. Their findings concern those assets, not this report.